GeoVax's Dual-Antigen COVID-19 Vaccine Targets Vulnerable Immunocompromised Populations

GeoVax Labs, Inc., a clinical-stage biotechnology company, has announced the publication of a peer-reviewed article in Medical Research Archives detailing its next-generation COVID-19 vaccine candidate, GEO-CM04S1. This dual-antigen vaccine, delivered via a Modified Vaccinia Ankara (MVA) viral vector, is specifically designed to address the limitations of first-generation vaccines in protecting immunocompromised populations, such as cancer patients, transplant recipients, and those on immunosuppressive therapies. The article provides a comprehensive review of the scientific rationale, preclinical studies, and clinical findings supporting GEO-CM04S1's development, highlighting its potential to generate broad and durable antibody and T-cell responses by targeting both the spike and nucleocapsid proteins of SARS-CoV-2.

Key scientific highlights from the publication include the vaccine's dual-antigen design, which aims to enhance immune breadth by targeting conserved viral proteins less susceptible to mutation. Preclinical and clinical data demonstrate robust CD4+ and CD8+ T-cell responses, critical for controlling viral infection and reducing severe disease progression. Early clinical studies have shown a favorable safety profile and strong immunogenicity, with encouraging results in immunocompromised patients, including those with hematologic malignancies and chronic lymphocytic leukemia. David Dodd, Chairman and CEO of GeoVax, emphasized that an estimated 40+ million immunocompromised patients in the U.S. and 400 million worldwide remain at higher risk of severe COVID-19 outcomes due to inadequate responses to current vaccines.

Mark J. Newman, PhD, Chief Scientific Officer and co-author, noted that GEO-CM04S1's design focuses on stimulating strong T-cell responses, which are essential for immunocompromised individuals who often fail to generate adequate antibody responses. The MVA vector platform is highlighted for its ability to safely induce durable immunity, while the dual-antigen strategy expands immune recognition beyond the spike protein, potentially reducing the need for frequent vaccine updates. GeoVax's broader pipeline includes other programs like GEO-MVA for mpox and smallpox, and Gedeptin® for oncology, with more information available at www.geovax.com. The company is advancing GEO-CM04S1 through multiple Phase 2 clinical trials, aiming to provide improved protection for vulnerable populations where first-generation vaccines have shown reduced effectiveness.